CAR T Cell Immunotherapy Beyond Haematological Malignancy

Chimeric antigen receptor (CAR) T cells, which express a synthetic receptor engineered to target specific antigens, have demonstrated remarkable potential to treat haematological malignancies. However, their transition beyond haematological malignancy has so far been unsatisfactory. Here, we discuss...

Descripción completa

Detalles Bibliográficos
Autores principales: Hupperetz, Cedric, Lah, Sangjoon, Kim, Hyojin, Kim, Chan Hyuk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association of Immunologists 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901698/
https://www.ncbi.nlm.nih.gov/pubmed/35291659
http://dx.doi.org/10.4110/in.2022.22.e6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901698/
https://www.ncbi.nlm.nih.gov/pubmed/35291659
http://dx.doi.org/10.4110/in.2022.22.e6

Ejemplares similares